May 12

Journal Article – Tirzepatide Versus Semaglutide for Obesity Treatment

by

This paper describes a phase 3b clinical trial comparing tirzepatide and semaglutide for weight management in adults with obesity but without diabetes. The SURMOUNT-5 trial randomly assigned participants to receive either tirzepatide or semaglutide weekly for 72 weeks. Tirzepatide was found to be superior to semaglutide in achieving greater reductions in both body weight and waist circumference. While both medications led to similar rates of overall adverse events, predominantly gastrointestinal, tirzepatide resulted … Read more

Ozempic’s double-sided coin: Amid skyrocketing popularity of GLP-1 drugs, a burgeoning lawsuit looms – Pittsburgh Post-Gazette

by

Ozempic’s double-sided coin: Amid skyrocketing popularity of GLP-1 drugs, a burgeoning lawsuit looms  Pittsburgh Post-Gazette Eli Lilly Sues 4 Telehealth Cos. For Weight Loss Drug Copies  Law360 Big Pharma Is Winning the Price War Over Weight Loss Drugs Like Ozempic: Will RFK Jr. and His MAHA Allies Push Back?  The New York Sun Navigating The GLP-1 Litigation Landscape  Life … Read more

Best fat jab revealed after first head-to-head trial shows patients see 20% weight loss

by

TWO blockbuster weight loss just have been tested against each other for the first time in a head-to-head trial. There was a clear winner, which saw slimmers shed 20 per cent of their body weight. AlamyMounjaro helped users lose up to 20 per cent of their body weight[/caption] AlamyMeanwhile, Wegovy saw people lose 13 per … Read more

Zepbound (tirzepatide) Showed Superior Weight Loss Over Wegovy (semaglutide) in Complete SURMOUNT-5 Results Published in The New England Journal of Medicine

by

INDIANAPOLIS, May 11, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of Zepbound (tirzepatide), a dual GIP and GLP-1…

Facebook Twitter
© Copyright 2025 GenWeb of Texas